Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer
About this episode
Smriti Patodia interviews Dr Andrea Necchi about his research on neoadjuvant therapy for muscle-invasive bladder cancer.
Smriti Patodia, Senior Editor of The Lancet Oncology, is joined by Dr Andrea Necchi, Associate Professor at the Vita-Salute San Raffaele University, and the Director of Genitourinary Medical Oncology at the San Raffaele Hospital, in Milan, Italy, to discuss his SunRISe4-trial published in our October issue. Effective treatments are needed for patients with muscle-invasive bladder cancer scheduled for radical cystectomy who are ineligible for or decline to receive neoadjuvant cisplatin-based ...
More episodes of The Lancet Oncology in conversation with
- Fred Saad on quality of life in patients with metastatic hormone-sensitive prostate cancer
- James Nagarajah on [177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study
- Ali Landman on the European Congress of Radiology 2026
- Kayleigh Bhangdia on breast cancer GBD study 2023
- Dylan Graetz and Erica Kaye on qualitative research in oncology
- Jesse Plascak and Marissa Baker on cancer mortality rates by occupation among US workers
Explore listener stats, chart rankings, contacts and more on the The Lancet Oncology in conversation with podcast page.